Results 61 to 70 of about 5,099,009 (221)

Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

Hematology, Transfusion and Cell Therapy, 2018
Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça, André Henrique Crepaldi, Márcia Torresan Delamain, Adriana Helena Moreira, Felipe D’Almeida Costa, Vladmir Cláudio Cordeiro de Lima, Cármino Antonio de Souza, Fernando Augusto Soares, José Vassallo   +8 more
doaj   +1 more source

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

EJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li   +7 more
doaj   +1 more source

CD5– Mantle Cell Lymphoma [PDF]

American Journal of Clinical Pathology, 2002
Mantle cell lymphoma (MCL) typically expresses B-cell antigens and CD5 and overexpresses bcl-1 protein. However, unusual cases of bcl-1+ and CD5-MCL have been observed, posing a practical challenge for correct diagnosis and management. We identified 25 cases (48 samples) of bcl-1+ and CD5- lymphoma.
Zach, Liu, Henry Y, Dong, Wojciech, Gorczyca, Patricia, Tsang, Patti, Cohen, Christine F, Stephenson, Carol S, Berger, C Daniel, Wu, James, Weisberger   +8 more
openaire   +2 more sources

Bortezomib‐based chemotherapy in Chinese pediatric patients with relapsed/refractory acute lymphoblastic leukemia: A single‐center retrospective study

Pediatric Investigation, EarlyView.
Bortezomib‐based chemotherapy achieved an 88.9% remission rate in Chinese pediatric patients with relapsed/refractory B‐cell acute lymphoblastic leukemia, enabling 62.5% of responders to bridge to transplantation, while T‐cell acute lymphoblastic leukemia showed no response.
Xingyu Zhao, Jian Wang, Liping Que, Dunhua Zhou, Jianpei Fang, Luhong Xu   +5 more
wiley   +1 more source

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop [PDF]

Leukemia & Lymphoma, 2010
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination.
Michael E, Williams, Joseph M, Connors, Martin H, Dreyling, Randy D, Gascoyne, Brad S, Kahl, John P, Leonard, Oliver W, Press, Wyndham H, Wilson   +7 more
openaire   +2 more sources

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Molecular Pathogenesis of MALT lymphoma [PDF]

, 2011
Mucosa associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway.

core   +2 more sources

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

Journal of Hematology & Oncology, 2010
Background Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported. Results
Quintin-Roué Isabelle, Morel Frederic, André Norbert, Eveillard Jean-Richard, Tempescul Adrian, Ianotto Jean-Christophe, Berthou Christian   +6 more
doaj   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

SLV-404, an anti-RYK antibody-drug conjugate, is effective in Richter transformation patient-derived xenografts. [PDF]

Hemasphere
Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients.
Micillo M, Pirajno B, Vallone FE, Navarro-Tableros V, Bolli E, Griggio V, Lannutti BJ, Jessen KA, Vaisitti T, Deaglio S.   +9 more
europepmc   +2 more sources